Articles tagged with Breast Cancer
Researchers found that macrophages are essential for embryo implantation in the uterus. The absence of these cells leads to reduced hormone levels, causing embryos to fail to implant. Restoration of macrophage function or hormone replacement therapy can revive pregnancy, shedding new light on a potential cause of infertility.
Researchers have identified microRNA-22 as a driver of both cancer onset and metastasis, particularly in breast cancer and blood cancers. The study suggests that inhibiting miR-22 through a 'decoy' method could offer a novel therapeutic option for treating these diseases.
The UNC team developed biomarkers for challenging molecular subtypes of human breast cancer using genetically engineered mouse models. They found that these models accurately predicted human response to chemotherapy drugs, providing valuable insights into breast cancer treatment.
Seventy percent of US plastic surgeons use fat grafting techniques for breast operations, with 88% using it for breast reconstruction. However, issues like mammography interference and unpredictable results are noted as potential obstacles.
A recent study has found a significant link between long-term night shifts and an increased risk of breast cancer. Women who worked night shifts for 30 or more years were twice as likely to develop the disease, highlighting the importance of workplace policy.
A high HOXB13/IL17BR ratio in tumor tissue indicates increased risk of recurrence after tamoxifen therapy, but drops significantly if a patient receives letrozole. This biomarker can help identify patients who may benefit from extended treatment with letrozole.
A team of Johns Hopkins graduate students has designed a device to inspect breast tissue in real-time, reducing the need for follow-up surgeries. The device applies an adhesive film to the tissue, preventing damage and allowing pathologists to quickly review samples within 20 minutes.
Researchers have developed a targeted viral therapy that selectively kills breast cancer stem cells and induces apoptosis without affecting normal stem cells. The therapy, which uses the mda-7/IL-24 gene, was shown to be effective in both cell culture and animal models, with no toxic effects on healthy cells.
A recent study by Mayo Clinic and others reveals that rural women with breast cancer are less likely to receive guideline-recommended radiation therapy after a lumpectomy. The researchers found that rural women were also more likely to choose mastectomy over lumpectomy, leading to potential gaps in care.
A new phase 2 trial is underway to evaluate the efficacy of HER-2 targeted regimens in elderly patients with HER-2 positive metastatic breast cancer. The study aims to delay or avoid conventional chemotherapy while maintaining tumor control.
CNIO researchers describe molecular bases of resistance to PARP inhibitor drugs in familial breast and ovarian cancers. Secondary mutations in genes like 53BP1 or PTIP can compensate for BRCA1/2 mutations, rendering drugs ineffective.
Research suggests that social stress can lead to increased metabolism in breast fat cells, which in turn stimulates nearby pre-cancerous cells to proliferate more rapidly. This local effect of fat cells in the breast may contribute to the development of triple-negative breast cancer.
Researchers have discovered a crucial signaling network between EGFR and MCM7 proteins, which plays a key role in DNA replication and cell growth. In breast cancer patients, high expression of Lyn and MCM7 is associated with reduced survival rates, highlighting a potential new target for cancer therapy.
Researchers found that medical specialists can identify abnormality in breast and cervical cancer images with high accuracy, outperforming random guessing. However, localizing the issue proves challenging even for experts.
Harvard researchers have identified the SALL4 gene as a key player in tumor formation, and have demonstrated that blocking its activity can halt cancer growth. The study provides new hope for treating aggressive forms of leukemia and other cancers.
Researchers identified a new molecular pathway involving the gene ZNF365 that may predict worse outcomes for patients with breast cancer. Abnormalities in this pathway can lead to genomic instability and an increased risk of developing tumors.
Researchers identified genetic variations associated with breast cancer risk among women on tamoxifen and raloxifene therapy. Women with favorable variations of the ZNF423 and CTSO genes are more likely to respond to prevention therapy, while those with unfavorable variations face a five-fold increased risk of developing breast cancer.
A study by University of Pennsylvania researchers found that the tumor suppressor protein Par-4 plays a crucial role in preventing breast cancer recurrence. Low Par-4 expression is associated with an increased risk of recurrence and poor response to chemotherapy, highlighting potential new therapeutic strategies.
Researchers at Case Western Reserve University found that gene HEXIM1 enhances heart health by increasing blood vessel growth, making hearts healthier and more efficient. HEXIM1 also suppresses breast cancer metastasis.
Researchers identified two gene variants that can predict which women are most likely to benefit from breast cancer prevention treatment and which should avoid it. The study found that women with the beneficial version of the two SNPs were 5.71 times less likely to develop breast cancer while taking preventive drugs.
A new study published in Cancer Discovery identified two genetic variations associated with breast cancer risk in women receiving preventive therapy. Women with favorable variations were more likely to respond to the therapy, while those with unfavorable variations had a five-fold increased risk of developing breast cancer.
A subgroup analysis from a phase III clinical trial found that eribulin demonstrated a greater potential benefit in overall survival compared to capecitabine for women with previously treated metastatic breast cancer. Specifically, patients with multiple organs involved, those who had not received chemotherapy for six months or longer,...
New research published by the University of Oxford found that breast cancer screening programs do not reduce mortality rates, contradicting previous findings. The study analyzed data from England over nearly 40 years and concluded that there is no evidence of a benefit from mammographic screening on breast cancer mortality.
Researchers found that none of the 169 cancer clinical practice guidelines met all eight criteria set by the Institute of Medicine. However, some guidelines were rated as 'good,' highlighting the need for a balance between ideal standards and practical implementation.
Researchers used parallel PET/MR imaging to map chemotherapy distribution before surgery, improving risk stratification and patient management. This study suggests simultaneous PET/MR imaging can benefit patients by predicting cancer recurrence and avoiding unnecessary chemotherapy.
A new study reveals low uptake of genetic testing for cancer-causing mutations in affected families in France. Despite steady increase in tests for BRCA1/2, MMR mutation testing remains under-used, putting whole families at risk.
A new study released by George Mason University researchers has shown success in pinpointing individualized treatment for women with metastatic breast cancer. The pilot study combined proteomic and genomic research, achieving a 30% increase in progression-free survival for nearly half of the patients.
Scientists have created a model to study breast cancer biology, confirming that primary tissue from patients behaves similarly to those derived from long-term cultured cell lines. This breakthrough advances the development of targeted therapies for advanced cancer treatments.
A University of Missouri researcher studied how stories influence patients' decision-making when behavior change is not the desired outcome. The study found that including patient stories in decision aids can make them more trustworthy and emotional, but may not affect treatment choice.
African-American women with breast cancer are more likely to carry inherited genetic mutations that increase their risk for breast cancer. Genetic testing can help identify at-risk family members and provide personalized strategies for early detection and prevention.
Researchers at Berkeley Lab identified the microenvironment surrounding microvasculature as a niche where dormant breast tumor cells reside. The study reveals that stable microvasculature suppresses growth and creates a dormant niche, while sprouting neovasculature sparks micrometastatic outgrowth.
A new Raman spectroscopy algorithm can accurately diagnose breast cancer and its associated lesions, reducing the need for repeat biopsies. The algorithm showed positive predictive values of 100% and negative predictive values of 96% for detecting breast cancer with or without microcalcifications.
Researchers discovered that nearly two-thirds of solid tumors have genetic mutations that can be targeted by existing compounds. This finding suggests that routine tumor sequencing may become a standard practice in cancer treatment, enabling doctors to personalize treatment regimens for patients.
A new study of young women with breast cancer found that most opted for a mastectomy rather than breast-conserving surgery. Factors associated with this choice included genetic mutations, tumor characteristics, and high levels of anxiety. The researchers hope to shed light on why rates of mastectomies are rising among younger patients.
Researchers at the University of Alberta have identified a genetic marker on chromosome 4 associated with sporadic breast cancer in Alberta women. The study, published in PLoS One, used DNA scans from over 7,200 women and found that those with sporadic breast cancer frequently carried this marker.
A new LSUHSC paper has been selected as the Best Paper of the Year by the National Cancer Registrars Association for its innovative evaluation of cancer stages. The study found that lung and prostate cancers had the highest percentages of unknown stages, with non-hospital reporting sources being a key predictor.
Researchers found that EGFR gummed up the cell's miRNA-processing machinery, preventing tumor-suppressing microRNAs from developing. The epidermal growth factor receptor, known to promote cancer progression, fuels this effect by attaching phosphate groups to a key protein, disrupting its ability to process miRNAs.
Researchers have identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer. The findings suggest a potential new approach to blocking metastasis in various cancers.
A study published in Journal of the American College of Surgeons found that 35% of Texas women diagnosed with a breast mass between 2000 and 2008 underwent unnecessary surgical biopsies. This represents thousands of women who had surgery unnecessarily, while also driving up healthcare costs.
Despite new recommendations, women in their 40s continue to get routine breast cancer screenings at the same rate as before, with insurance coverage being a key reason for persistence. The study's findings highlight the ongoing challenges in changing behavior and the influence of societal factors on individual decisions.
A clinical trial led by Penn Medicine found that olaparib was effective against advanced pancreatic and prostate cancers in patients carrying BRCA 1/2 mutations. The therapy showed promise in halting disease progression, even in patients whose tumors did not shrink.
Breast cancer survivors who underwent cognitive training showed significant improvement in executive function, verbal fluency, and processing speed. The study suggests online cognitive training as an intervention for cognitive difficulties in breast cancer survivors.
The UIC Center for Clinical and Translational Science has selected six research projects to receive $30,000 per year pilot grants. These grants aim to support the development of new ideas and generate preliminary data for applying for highly competitive grants from outside sources.
A new study suggests that digital direct radiography (DR) is significantly more effective than computed radiography (CR) in detecting breast cancer. DR detected 4.9 cancers per 1,000 mammograms, while CR's detection rate was 21% lower, with 3.4 cancers per 1,000 mammograms.
A nationwide study will examine the influence of genetic testing on clinical treatment decisions among breast cancer patients and their doctors. The 5-year American BRCA Outcomes Among the Recently Diagnosed (ABOARD) study will follow 5,000 Aetna members and provide critical information to improve personalized health care.
A new study found that metformin, a commonly used diabetes drug, did not improve survival rates in older breast cancer patients with diabetes. The study, published in Diabetes Care, examined 2,361 women aged 66 or older and followed them until death or March 30, 2010.
Researchers identified immune gene signatures that predict cancer recurrence in certain breast cancer types, such as basal-like or triple negative disease. These signatures can help doctors make informed treatment decisions and may lead to valuable new strategies in personalized medicine.
A Kaiser Permanente study found that breast cancer patients with strong social relationships, especially positive social interaction, reported improved physical quality of life and reduced pain. Tangible support, such as help with daily tasks, was also crucial for late-stage patients.
A new study found that Black women with breast cancer are three times more likely to delay treatment for over 90 days compared to white women. Low satisfaction with doctor communication is a significant reason for this delay, which increases the risk of mortality from the disease.
Researchers discovered that combining a few microRNAs enhances anti-breast cancer activity without the unwanted side effects of amplifying a single microRNA. This technique targets tumor-specific genes while sparing healthy tissue.
Researchers have discovered that breast cancer patients with dense breasts are more likely to develop aggressive tumors. A protein called DDR2 plays a key role in this process, facilitating the spread of cancer cells by activating a multistep pathway.
A recent study published at the 5th IMPAKT Breast Cancer Conference finds that gene expression tests can effectively tailor cancer treatments to individual patients, despite variability in tumor cell types and gene expression. The researchers analyzed 78 biopsies from 26 tumors and found that some genomic tests were more reliable than ...
A study found a statistically non-significant but clinically significant benefit in adding everolimus to trastuzumab treatment for HER-2 positive early breast cancer. The combination improved clinical response rates, but not pathological response rates, suggesting benefits independent of expected molecular pathways.
A new analysis compared five different scores to predict late recurrence in estrogen-receptor positive breast cancer patients. The Clinical Treatment Score was found to be the best predictor of late recurrence, while the PAM50 Risk of Recurrence and Breast Cancer Index scores added significant prognostic value.
A recent study has revealed the magnitude of variation in gene expression measurements within breast cancers. Combining samples from multiple biopsies from a single tumour can effectively overcome this variation for selected genes, allowing for more precise treatment tailoring and reliable predictions related to disease progression.
Researchers use modern sequencing technology to characterize genetic aberrations in advanced postmenopausal breast cancer patients. The study found that tumours with similar clinical profiles can have distinct genetic characteristics, suggesting the need for tailored treatment strategies.
A gene expression test measures 58 genes in oestrogen receptor-positive breast cancers to differentiate between patients with high and low risk of late recurrence. The test provided significant prognostic information for late distant-relapse-free survival, with better individual risk prediction for women.
A new study found that adding genomics-based testing to the standard diagnostic workup could lead to a change in recommended treatment for some women. The research identified four novel genomic-based subtypes of endometrial cancer, which suggest that genetic changes can help guide treatment decisions.
A large-scale genomic analysis identified distinct subtypes of endometrial cancer based on their genomic makeup, which may respond to targeted drugs already being tested in clinical trials. The findings suggest that a significant portion of high-grade endometrioid tumors should be treated more aggressively after surgery.
Two studies from The Cancer Genome Atlas program reveal genomic landscapes of AML and endometrial cancer, providing new insights into molecular underpinnings. The studies identify four novel tumor subtypes in endometrial cancer and show genomic similarities with other types of cancers.